The monoclonal antibody glembatumumab vedotin (GV) targets a type I transmembrane glycoprotein, named glycoprotein non-metastatic B (gpNMB), which enhances cellular growth and metastatic potential, and has been found to be frequently overexpressed in osteosarcoma cells [77,78]. The gene discussed is GPNMB; the disease is osteosarcoma.